The development of human hematopoietic prostaglandin D2 synthase inhibitors in allergic asthma and related disorders

人类造血前列腺素 D2 合酶抑制剂在过敏性哮喘及相关疾病中的开发

• 批准号: nhmrc : 1039255
• 负责人: A/Pr Mark Smythe
• 金额: $ 28.54万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-human-hematopoietic-related-disorders/111265
• 关键词: development; human; hematopoietic; prostaglandin; D2

Prostaglandin D2 (PGD2) is a key mediator of asthma and allergic rhinitis. We have developed drug-like compounds that block the synthesis of PGD2 by inhibiting the hematopoietic prostaglandin D2 synthase (HPGD2S) enzyme. This project aims to evaluate the potential of these compounds to treat asthma and to further optimize the drug-like characteristics of our lead molecules.

前列腺素D2（PGD2）是哮喘和过敏性鼻炎的关键介质。我们已经开发了药物样化合物，通过抑制造血前列腺素D2合成酶（HPGD 2S）来阻断PGD 2的合成。该项目旨在评估这些化合物治疗哮喘的潜力，并进一步优化我们的先导分子的药物样特征。